Belite Bio, Inc. (BLTE) Income Statement
BLTE 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBLTE revenue and net income
BLTE growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BLTE quarterly EPS vs estimates
Belite Bio beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 9, 2026 (estimate $-0.73).
BLTE income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $449,000 | $399,000 | $198,000 | $30,000 | $17,000 |
| Gross profit | — | −$449,000 | −$399,000 | −$198,000 | −$30,000 | −$17,000 |
| Research & development | $45.4M | $29.9M | $24.8M | $8.9M | $7.4M | $3.7M |
| Sales, general & admin | $38.8M | $10.1M | $7.2M | $4.0M | $2.4M | $2.1M |
| Total operating expenses | $84.2M | $40.0M | $31.7M | $12.8M | $9.8M | $5.7M |
| Operating income | −$84.2M | −$40.0M | −$31.7M | −$12.8M | −$9.8M | −$5.7M |
| Interest income | $6.6M | $3.7M | $74,000 | $23,000 | $5,000 | $12,000 |
| Interest expense | $2,000 | $20,000 | $25,000 | $16,000 | $5,000 | $21,000 |
| Income before taxes | −$77.6M | −$36.1M | −$31.6M | −$12.6M | −$9.7M | −$5.8M |
| Income taxes | — | $6,000 | $9,000 | −$173,000 | $126,000 | $1,000 |
| Net income | −$77.6M | −$36.1M | −$31.6M | −$12.6M | −$9.7M | −$5.8M |
| EBITDA | −$77.1M | −$35.7M | −$31.2M | −$12.4M | −$9.6M | −$5.7M |
| EPS (diluted) | −$2.30 | −$1.18 | −$1.24 | −$1.08 | −$0.20 | −$0.65 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $18.2M | $15.7M | $14.6M | $10.3M | $11.0M | $9.4M | $7.3M | $6.8M | $9.1M | $9.1M | $4.9M | $8.7M |
| Sales, general & admin | $16.7M | $17.0M | $13.5M | $12.7M | $6.5M | $6.1M | $4.2M | $2.9M | $1.4M | $1.4M | $2.1M | $2.2M |
| Total operating expenses | $34.9M | $32.7M | $28.1M | $23.0M | $17.6M | $15.5M | $11.5M | $9.7M | $10.5M | $10.5M | $7.0M | $11.0M |
| Operating income | −$34.9M | −$32.7M | −$28.1M | −$23.0M | −$17.6M | −$15.5M | −$11.5M | −$9.7M | −$10.5M | −$10.5M | −$7.0M | −$11.0M |
| Interest income | — | — | $3.2M | — | — | — | — | — | — | — | — | — |
| Income before taxes | −$28.4M | −$26.9M | −$25.3M | −$21.7M | −$16.3M | −$14.3M | −$10.1M | −$8.7M | −$9.5M | −$9.5M | −$7.0M | −$10.9M |
| Income taxes | $55,000 | — | — | — | — | — | — | — | — | $6,000 | −$1,000 | $1,000 |
| Net income | −$28.4M | −$26.9M | −$25.3M | −$21.7M | −$16.3M | −$14.3M | −$10.1M | −$8.7M | −$9.5M | −$9.5M | −$7.0M | −$10.9M |
| EBITDA | −$34.9M | −$26.9M | −$30.7M | −$21.7M | −$16.3M | −$14.2M | −$7.6M | −$8.6M | — | −$9.5M | −$6.9M | −$10.9M |
| EPS (diluted) | −$0.70 | −$0.68 | −$0.70 | −$0.65 | −$0.50 | −$0.45 | −$0.32 | −$0.28 | −$0.31 | −$0.27 | −$0.25 | −$0.40 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BLTE's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BLTE financial results
Belite Bio reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $77.6 million. Diluted earnings per share came to −$2.30.
See the BLTE stock overview for the latest quote and news, or the BLTE chart for price history and technical indicators.
BLTE income statement FAQ
Does Belite Bio have revenue?
Belite Bio reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Belite Bio profitable?
No. Belite Bio reported a net loss of $77.6 million in fiscal 2025.
How much does Belite Bio spend on research and development?
Belite Bio spent $45.4 million on research and development in fiscal 2025.
What are Belite Bio's earnings per share?
Belite Bio earned $-2.30 per diluted share in fiscal 2025, compared with $-1.18 a year earlier.
When will Belite Bio report its next earnings?
Belite Bio is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes.
When does Belite Bio's fiscal year end?
Belite Bio's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.